The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental Biologics License Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE